Desert Oasis Healthcare Partners with Rimidi to Help Improve Asthma Management for Patients using Teva Digihaler® Technology
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: PR Web
ATLANTA (PRWEB) March 21, 2023 Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that Desert Oasis Healthcare (DOHC), a leading regional medical group and Rimidi customer of over eight years, has implemented Rimidi's new Respiratory Module. Designed to give providers a more complete view of the patient in order to guide treatment decisions for those with respiratory diseases such as chronic obstructive pulmonary disease (COPD) or asthma, the Respiratory Module is enhanced by a collaboration with Teva Pharmaceuticals. Data from Teva's Digihaler family of digital inhalers is brought into clinical workflows via the Rimidi platform, allowing for efficient management of COPD and asthma within the clinician's existing electronic health record.The implementation of the Respiratory Module with DOHC marks a unique collaboration between pharma and a clinical management platform, pr
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)Business Wire
- Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies [Yahoo! Finance]Yahoo! Finance
- Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets [Yahoo! Finance]Yahoo! Finance
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsBusiness Wire
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/31/24 - Beat
TEVA
Sec Filings
- 4/18/24 - Form 8-K
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form ARS
- TEVA's page on the SEC website